Date | Product | Disease | Phase | Company | Therapeutic area |
---|---|---|---|---|---|
2012-11-14 | genetics relating to lung disease | chronic obstructive pulmonary disease (COPD) |
genetic study | Medical Research Council - MRC (UK) Nottingham University (UK) Leicester University (UK) | Respiratory diseases - Lung diseases |
2012-11-13 | AM-111 | acute sensorineural hearing loss (ASNHL) | 2b | Auris Medical (Switzerland) | Otorhinolaryngology |
2012-11-13 | TG4001 | HPV16 positive oropharyngeal squamous cell carcinomas |
2b | Transgene (France) EORTC (EU) | Cancer - Oncology |
2012-11-12 | TNF-Kinoid® | rheumatoid arthritis | 2a | Neovacs (France) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2012-11-12 | CP-4126 | 2 | Clavis Pharma (Norway) - Clovis Oncology (USA) | Cancer - Oncology | |
2012-11-12 | MOR103 (antibody targeting granulocyte-macrophage colony-stimulating factor - GM-CSF) | chronic inflammatory diseases |
1 | Morphosys (Germany) | Autoimmune diseases - Inflammatory diseases |
2012-11-11 | ACZ885 (canakinumab) | Familial Mediterranean Fever (FMF) |
2 | Novartis (Switzerland) | Rare diseases - Inflammatory diseases |
2012-11-11 | ACZ885 (canakinumab) | tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) |
2 | Novartis (Switzerland) | Rare diseases - Inflammatory diseases |
2012-11-10 | type 1 diabetes | Sanofi (France) T1D Exchange (USA) | Metabolic diseases | ||
2012-11-09 | QNASL® (beclomethasone dipropionate) | seasonal allergic rhinitis (SAR) |
3 | Teva Pharmaceutical Industries (Israel) | Allergic diseases - Immune diseases |
2012-11-08 | T-Track® TB test | tuberculosis | Lophius Biosciences (Germany) | Infectious diseases | |
2012-11-08 | AllerT | birch pollen allergy | 1-2a | Anergis (Switzerland) | Allergic diseases - Immunological diseases |
2012-11-07 | RG7212 | advanced solid tumors | 1 | Roche (Switzerland) | Cancer - Oncology |
2012-11-07 | ATSP-7041 | preclinical data | Aileron Therapeutics (USA) Roche (Switzerland) | Cancer - Oncology | |
2012-11-06 | SAR236553/REGN727 | patients with heterozygous familial hypercholesterolemia (heFH) |
2 | Sanofi (France) Regeneron Pharmaceuticals (USA - NY) | Cardiovascular diseases - Genetic diseases - Rare diseases |
2012-11-06 | PFKFB3 inhibiting compounds | pancreatic cancer | preclinical data | Kancera (Sweden) | Cancer - Oncology |
2012-11-06 | MOR103 | rheumatoid arthritis |
1b-2a | Morphosys (Germany) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2012-11-05 | AMG 232 | advanced solid tumors, glioblastoma, multiple myeloma | 1 | Amgen (USA - CA) | Cancer - Oncology |
2012-11-05 | SAR236553/REGN727 | evaluation of the incidence of cardiovascular events in patients who have experienced an ACS and are not at their LDL-C goal |
3 | Sanofi (France) Regeneron Pharmaceutical (USA) | Cardiovascular diseases - Metabolic diseases |
2012-11-05 | ADX71149 (JNJ-40411813) | schizophrenia | 2a | Ortho-McNeil-Janssen Pharmaceuticals J&J (USA) Addex Therapeutics (Switzerland) | Mental diseases |